On Tuesday, Shares of Micron Technology, Inc.(NASDAQ:MU), subtract -3.66% and closed at $16.86 in the last trading session. The last trading range of the stock ranges between $16.53 and $17.47. The company’s Market capitalization is $17.40 Billion with the total Outstanding Shares of 1.04 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $9.31 and reached to max level of $19.30. The CCIX consortium recently declared that it has tripled its membership and has released the specification to consortium members. Founding members, AMD, ARM, Huawei, IBM, Mellanox Technologies, Qualcomm Technologies Inc., and Xilinx, Inc., welcome new members representing silicon providers and ecosystem partners in design, verification, software, and systems:
Avery Design Systems
Cadence Design Systems, Inc.
Integrated Device Technology, Inc.
Keysight Technologies, Inc.
Micron Technology, Inc.
Red Hat Inc.
CCIX allows processors based on different instruction set architectures to extend their cache coherency to accelerators, interconnect, and I/O. These highly capable accelerators become a key component in the processor system. The availability of the CCIX technology gives system designers the flexibility to choose the right combination of heterogeneous components from multiple vendors and address their specific system needs.
Boston Scientific Corporation (NYSE:BSX), dropped -2.57% and closed at $23.16 in the last trading session. The last trading range of the stock ranges between $23.01 and $23.74. The company’s Market capitalization is $31.90 Billion with the total Outstanding Shares of 1.36 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $15.67 and reached to max level of $24.79. – Boston Scientific Corporation (BSX) declared recently that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his new position, Professor Meredith will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company’s clinical trial strategy.
Professor Meredith will succeed Executive Vice President and Global Chief Medical Officer Keith Dawkins, M.D., who has declared his intention to retire from the company in January 2017.
“Ian is one of the world’s leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.”